Clinical Trial Update: Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability comparison of NVA237 (glycopyrronium) versus tiotropium in Japanese COPD patients completed; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-01-18